Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody
US7932048B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 9, 2006 |
| Grant date | Apr 26, 2011 |
| Priority date | — |
| Expiry date | Mar 13, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the β-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the β-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the β-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.